Christopher Ripperda, MD
Urogynecology and Reconstructive Pelvic Surgery · Fort Worth, TXNPI 1790001360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Medtronic at 54.7% of the total. Reporting peaked in 2021 at $956 and has fallen 68.3% since, to $303 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TX, where the typical reported total is $5,014.
Across 85 payments — averaging $41.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Axonics, Inc.$969
- Caldera Medical, Inc$314
- Boston Scientific$271
- Johnson & Johnson$33
- Aspira Women's Health Inc$19
- plus $6 from 1 others
What the payments were for
- Food & beverage$3,40396%
- Education$562%
- Gifts$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 52 | $1,942 |
| Axonics, Inc. | 22 | $969 |
| Caldera Medical, Inc | 6 | $314 |
| Boston Scientific | 2 | $271 |
| Johnson & Johnson | 1 | $33 |
| Aspira Women's Health Inc | 1 | $19 |
| Intuitive Surgical | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,553 in reported general payments places this provider in the 40th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 156 | $105,523 |
| MyrbetriqMirabegron | 40 | $32,626 |
| Estradiol | 145 | $10,758 |
| Fosfomycin Tromethamine | 39 | $6,468 |
| Methenamine Hippurate | 42 | $2,740 |
| Naloxone Hcl | 22 | $1,303 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $449 |
| Clobetasol Propionate | 13 | $358 |
| Tramadol Hcl | 108 | $212 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $162 |
| Amitriptyline Hcl | 13 | $127 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $37 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Fort Worth
- Wendy LengFort Worth$10K
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
- Teresa IrwinSan Marcos$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.